Impact of Solutol HS 15 on the pharmacokinetic behavior of midazolam upon intravenous administration to male Wistar rats

In Vivo Imaging of a New Indocyanine Green Micelle Formulation in an Animal Model of Laser-Induced Choroidal Neovascularization

“…36,38,[43][44][45][46][47] Kolliphor HS 15, which was used in this study, has been tested broadly as surfactant in drug formulation, and has shown high tolerability and safety in many biological systems. [48][49][50] These reports are in accordance with no observations of any toxic effects of micellar formulated ICG or Dye700 in vivo (Fig. 3) or ex vivo (Fig.…”

Changes of midazolam pharmacokinetics in Wistar rats treated with lipopolysaccharide: relationship between total CYP and CYP3A2

“…Furthermore, 1-hydroxymidazolam (1-OH-midazolam), a metabolite of midazolam, was assayed to evaluate effects on hepatic CYP3A2 activities. 13,14 …”

Tissue Distribution of Indinavir Administered as Solid Lipid Nanocapsule Formulation in mdr1a (+/+) and mdr1a (−/−) CF-1 Mice

“…The minor components, polyethyleneglycol stearic or oleic ester derivatives, in particular diesters, were found to be efficient P-gp inhibitors in vitro (19,41,42). Previous in vivo studies aiming at evaluating the effect of Solutol \ HS15, alone, on pharmacokinetics of intravenously administered drugs reported contradictory results (43,44). An alteration of the pharmacokinetic parameters in Wistar rats was observed for colchicin (43), but not for midazolam (44).…”

“…Previous in vivo studies aiming at evaluating the effect of Solutol \ HS15, alone, on pharmacokinetics of intravenously administered drugs reported contradictory results (43,44). An alteration of the pharmacokinetic parameters in Wistar rats was observed for colchicin (43), but not for midazolam (44). The component(s) of Solutol \ HS15 that presented P-gp inhibiting properties in vitro may therefore be of limited efficiency in vivo when administered alone or when included into LNC formulations.…”